Copyright
©The Author(s) 2016.
World J Hepatol. Feb 28, 2016; 8(6): 331-339
Published online Feb 28, 2016. doi: 10.4254/wjh.v8.i6.331
Published online Feb 28, 2016. doi: 10.4254/wjh.v8.i6.331
Table 4 Adverse events (≥ 20% in any treatment arm) n (%)
| Boceprevir plus PR (n = 159) | PR (n = 78) | |
| Any AE | 155 (97.5) | 71 (91.0) |
| Neutropenia | 84 (52.8) | 31 (41.0) |
| Pyrexia | 77 (48.4) | 36 (46.2) |
| Anemia | 75 (47.2) | 19 (24.4) |
| Leukopenia | 62 (39.0) | 25 (32.1) |
| Dysgeusia | 59 (37.1) | 3 (3.8) |
| Asthenia | 44 (27.7) | 23 (29.5) |
| Headache | 43 (27.0) | 25 (32.1) |
| Influenza-like illness | 39 (24.5) | 14 (17.9) |
| Nausea | 39 (24.5) | 9 (11.5) |
| Anemia | ||
| 8.5-10 g/dL | 56 (35.2) | 9 (11.5) |
| < 8.5 g/dL | 10 (6.3) | 2 (2.6) |
| Ribavirin dose reduction | 65 (40.9) | 14 (17.9) |
| EPO use | 15 (9.4) | 3 (3.8) |
| Serious AE | 17 (10.7) | 9 (11.5) |
| Discontinued because of an AE | 7 (4.4) | 2 (2.6) |
| Dose modification due to an AE | 89 (56.0) | 26 (33.3) |
- Citation: Isakov V, Nikitin I, Chulanov V, Ogurtsov P, Lukyanova E, Long J, Wahl J, Helmond FA, The P08160 Trial Investigators. Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World J Hepatol 2016; 8(6): 331-339
- URL: https://www.wjgnet.com/1948-5182/full/v8/i6/331.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i6.331